All In Biotech

Drug Trial Radar · NCT05701774

Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

An Open-Label Study of DCCR (Diazoxide Choline) Extended-Release Tablets in Patients With Prader-Willi Syndrome

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

77

Actual

Start

Jan 31, 2023

Primary completion

Jan 12, 2026

Study completion Apr 29, 2026

Sponsor

Lead sponsor
Soleno Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jan 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this is study is to evaluate the long-term safety of DCCR (diazoxide choline) extended-release tablets) in patients with Prader-Willi syndrome.

Conditions

  • Prader-Willi Syndrome

Interventions

  • DCCRDrug

    Once daily oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of DCCR (adverse events. Safety analyses will be conducted in all subjects who receive at least one dose of DCCR in the C614 study. ( Adverse events)Time frame: Baseline to End of Study or until resolution of certain adverse events

Locations

22 sites in 2 countries. Site status is shown where the registry gives one.

  • Soleno Clinical Site

    Orange, California

  • Soleno Clinical Site

    Palo Alto, California

  • Soleno Clinical Site

    San Diego, California

  • Soleno Clinical Site

    Gainesville, Florida

  • Soleno Clinical Site

    Atlanta, Georgia

  • Soleno Clinical Site

    Indianapolis, Indiana

  • Soleno Clinical Site

    Bethesda, Maryland

  • Soleno Clinical Site

    Boston, Massachusetts

  • Soleno Clinical Site

    Lansing, Michigan

  • Soleno Clinical Site

    Saint Paul, Minnesota

  • Soleno Clinical Site

    Paterson, New Jersey

  • Soleno Clinical Site

    Mineola, New York

  • Soleno Clinical Site

    Columbus, Ohio

  • Soleno Clinical Site

    Nashville, Tennessee

  • Soleno Clinical Site

    Dallas, Texas

  • Soleno Clinical Site

    Salt Lake City, Utah

  • Soleno Clinical Site

    Seattle, Washington

  • Fulbourn Hospital

    Cambridge, United Kingdom

  • Soleno Clinical Site

    Glasgow, United Kingdom

  • Soleno Clinical Site

    Hull, United Kingdom

  • Soleno Clinical Site

    London, United Kingdom

  • Soleno Clinical Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.